Wikisage, the free encyclopedia of the second generation, is digital heritage
Lamictal XR: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
(→Links) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
lamotrigine slow release<ref>https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal_XR/pdf/LAMICTAL-XR-PI-MG.PDF</ref> | [[lamotrigine]] slow release<ref>https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal_XR/pdf/LAMICTAL-XR-PI-MG.PDF</ref> | ||
risk increases conmmitant administration with valproate | risk increases conmmitant administration with valproate | ||
| Line 11: | Line 11: | ||
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf | http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf | ||
{{wikidata|Q410346}} | |||
lamotrigine | |||
{{refs}} | |||
Latest revision as of 23:26, 29 January 2023
lamotrigine slow release[1] risk increases conmmitant administration with valproate
Stevens Johnson has been observed in 8 per 1000 cases
this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.
Links
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf
lamotrigine
| References: |